Poor
Not Aligned
Patient Risk:
Moderate
Summary
Many key safety/use claims are either unsupported or likely inconsistent with the provided label excerpts (e.g., specific blood glucose thresholds, 10-minute onset, emergency use scenarios, shelf-life at room temperature, side-effect frequencies, and training/price/insurance claims). Only the core indication/mechanism-related items align with the supplied label information.
Category Scores
Accurate Statements
Gvoke (glucagon injection) treats severe hypoglycemia in people with diabetes when they cannot consume sugar quickly.
Supported by indication for subcutaneous treatment of severe hypoglycemia in adults and pediatric patients aged ≥2 years with diabetes (Sections 1.1, 2.1). The excerpt does not specify the 'cannot consume sugar quickly' phrasing, but the overall severe hypoglycemia treatment indication is aligned.
Gvoke works by prompting the liver to release stored glucose.
Supported by mechanism of action: stimulates glycogen breakdown and release of glucose from the liver (Section 12.1).
The FDA approved Gvoke in 2019 specifically for emergency use.
Not supported by provided excerpts; cannot verify approval year or 'specifically for emergency use' from the supplied label sections.
Gvoke is for emergency use when the person cannot swallow.
Not supported by provided excerpts (no administration scenario details such as inability to swallow).
Unsupported Statements
Gvoke is an emergency rescue medication for use when the person is unconscious or having seizures.
Provided label excerpts do not describe unconsciousness/seizure criteria.
Gvoke raises blood glucose rapidly.
No onset/rapidity claim in provided excerpts.
Gvoke raises blood glucose within 10 minutes.
No 'within 10 minutes' timeframe in provided excerpts.
Gvoke is administered by caregivers using a prefilled syringe or autoinjector.
Provided excerpts confirm presentations for subcutaneous use (HypoPen/PFS/Kit) but do not explicitly state caregiver administration.
Gvoke is approved for emergency use in adults.
Provided excerpts establish indication for severe hypoglycemia treatment but do not use the wording 'emergency use' for adults.
Gvoke is approved for emergency use in children over 2 years old.
Provided excerpts support pediatric age ≥2 years for severe hypoglycemia, but not 'emergency use' wording; also 'over 2' vs '2 years and older' not verifiable here.
Gvoke should be injected if blood sugar is below 54 mg/dL.
No blood glucose threshold guidance in provided excerpts.
Gvoke should be injected if blood sugar is below 70 mg/dL with symptoms.
No threshold guidance in provided excerpts.
After using Gvoke, 911 should be called.
No post-administration emergency services instruction in provided excerpts.
The effects of Gvoke last 1 to 1.5 hours.
No duration-of-effect claim in provided excerpts.
After using Gvoke, recurrence should be monitored.
No recurrence/monitoring instruction in provided excerpts.
Gvoke is available as a prefilled syringe or autoinjector.
Provided excerpts list HypoPen, PFS, and Kit but do not state 'autoinjector' specifically in the supplied text.
Gvoke has a shelf life of 2 years at room temperature.
No storage/shelf-life information in provided excerpts.
Gvoke is a needle-free option available.
Prefilled syringe/autoinjector is not supported as 'needle-free'; no 'needle-free' language in provided excerpts.
Gvoke avoids reconstitution.
No reconstitution guidance in provided excerpts.
Gvoke is manufactured by Xeris Pharmaceuticals.
No manufacturer information in provided excerpts.
Gvoke is available by prescription.
No prescription-status information in provided excerpts.
Gvoke is covered by most insurance for emergency kits.
No payer/coverage information in provided excerpts.
Gvoke costs $250-400 per two-pack without coverage.
No pricing information in provided excerpts.
Common side effects of Gvoke in emergency use include nausea.
No adverse reaction list with frequencies in provided excerpts.
Nausea occurs in 30% of emergency users.
No incidence/frequency data in provided excerpts.
Common side effects of Gvoke in emergency use include vomiting.
No adverse reaction list with frequencies in provided excerpts.
Vomiting occurs in 10% of emergency users.
No incidence/frequency data in provided excerpts.
Common side effects of Gvoke in emergency use include headache.
No adverse reaction list with frequencies in provided excerpts.
Rare side effects of Gvoke include high blood pressure.
Provided excerpts mention substantial increase in blood pressure in patients with pheochromocytoma as an adverse reaction; the claim 'rare side effects' and general 'high blood pressure' frequency is not supported.
Rare side effects of Gvoke include allergic reactions.
Provided excerpts do not mention allergic reactions as adverse reactions.
Users should be trained via demo devices.
No training/education via demo device language in provided excerpts.
Contradictions
Low
AI Statement
Gvoke has a shelf life of 2 years at room temperature.
Label Reference
Label excerpts provided do not state this; however, contradiction cannot be established without explicit conflicting label text in the supplied excerpts.
Important Omissions
Correct pediatric dosing by weight/age (e.g., 0.5 mg for <45 kg; 1 mg for ≥45 kg; possible repeat dose if no response after 15 minutes) and adult dosing (1 mg; repeat after 15 minutes if no response).
Importance:
Moderate
Key limitation/precaution: lack of efficacy with subcutaneous use in patients with decreased hepatic glycogen.
Importance:
Moderate
Contraindications (pheochromocytoma, insulinoma, prior hypersensitivity to glucagon/excipients; and glucagonoma for GVOKE VialDx).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several potentially safety-relevant details were unsupported by the provided label excerpts (e.g., blood glucose cutoffs, onset time, emergency action instructions, and adverse-event frequencies). Missing label-supported contraindications and the specific precaution regarding decreased hepatic glycogen further reduce on-label accuracy for safe use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Many claims are not supported by the provided label excerpts, including specific thresholds, timing, side-effect frequencies, storage/price/coverage, and training instructions.
Suggested Improvement
Limit statements to label-supported content from the provided sections: indication (severe hypoglycemia treatment for ≥2 years with diabetes via subcutaneous injection), labeled dosing and repeat-dose timing (15 minutes; weight-based pediatric dosing), and label-supported mechanism/precaution (hepatic glycogen limitation). Remove or qualify any unsupported numerical thresholds, onset/duration claims, frequency statements, and non-label logistical facts.